title: Churg-Strauss syndrome and the leukotriene receptor antagonist pranlukast.
abstract: The authors studied eight cases of Churg-Strauss syndrome (CSS) associated with the use of pranlukast, a common cysteinyl leukotriene receptor antagonist (LTRA) in Japan. The patients who received pranlukast showed significantly increased peripheral blood eosinophil count, neurological disability scores, and poor responses to corticosteroid in comparison with those patients not receiving pranlukast. We suggest that preceding administration of pranlukast aggravates clinical presentations of CSS.
authors.forename: Junsuke
authors.initials: J
authors.lastname: Shimbo
authors.forename: Osamu
authors.initials: O
authors.lastname: Onodera
authors.forename: Keiko
authors.initials: K
authors.lastname: Tanaka
authors.forename: Shoji
authors.initials: S
authors.lastname: Tsuji
mesh_terms: D018927:Anti-Asthmatic Agents / Q000009:adverse effects*; D001249:Asthma / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D002867:Chromones / Q000009:adverse effects*; D015267:Churg-Strauss Syndrome / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D020024:Leukotriene Antagonists / Q000009:adverse effects*; D012189:Retrospective Studies; D012720:Severity of Illness Index
chemical_list: D018927:Anti-Asthmatic Agents; D002867:Chromones; D020024:Leukotriene Antagonists; C047681:pranlukast